Single wall nanotube constructs and uses thereof

Patent metadata

Field	Value
Publication number	US-11564988-B2
Application number	US-201916564322-A
Country	US
Kind code	B2
Filing date	Sep 9, 2019
Priority date	Jul 29, 2005
Publication date	Jan 31, 2023
Grant date	Jan 31, 2023

Abstract

The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

First claim

What is claimed is:

1. A method of delivering an anticancer drug in situ to a cancer in a subject, comprising:
administering a first component of a soluble single wall carbon nanotube (SWNT) construct having the structure SWNT-(peptide) x -(DNA 1 ) x -(DNA 2 ) x , said peptide targeting cells comprising the cancer; administering a second construct component having the structure cDNA 1 -E 1 ) m and a third construct component having the structure (cDNA 2 -E 2 ) n ;
self-assembling said soluble SWNT construct in situ via hybridization of the second and third construct components to the first construct component, said selfassembled SWNT construct having the structure SWNT-(peptide) x -(DNA 1,2 -(cDNA 1 -E 1 ) m -(cDNA 2 -E 2 ) n ) x , wherein
x is 1 to 300;
m and n are independently 1 to 300;
cDNA 1 and cDNA 2 are non-identical oligonucleotides;
DNA 1 and DNA 2 are oligonucleotides with sequences complementary to cDNA 1 and cDNA 2 ; and
E 1 and E 2 are enzymes;

administering an anticancer preprodrug to the subject; and
activating the drug via sequential action of the enzymes on the preprodrug thereby delivering said anticancer drug in situ to the cancer in the subject.

2. The method of claim 1 , wherein cDNA 1 and cDNA 2 have about 8 to about 100 nucleotides and DNA 1,2 has about 16 to about 200 nucleotides.

3. The method of claim 2 , wherein cDNA 1 has the sequence shown in SEQ ID NO: 2 and cDNA 2 has the sequence shown in SEQ ID NO: 3.

4. The method of claim 1 , wherein E 1 is carboxypeptidase A and E 2 is β-glucuronidase.

5. The method of claim 1 , wherein said preprodrug is preprodoxirubicin.

6. The method of claim 5 , wherein said self-assembled SWNT construct comprises an enzymatic nanofactory.

Assignees

• Scheinberg David A
• Mcdevitt Michael R
• Antczak Christophe
• Chattopadhyay Debjit
• May Rena
• Njardarson Jon
• Phillips Mark Reid
• Sloan Kettering Inst Cancer Res

Inventors

• Scheinberg David A
• Mcdevitt Michael R
• Antczak Christophe
• Chattopadhyay Debjit
• May Rena
• Njardarson Jon
• Phillips Mark Reid

Classifications

• B82Y30/00

  Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title

• C01B32/174

  Derivatisation; Solubilisation; Dispersion in solvents · CPC title

• C01B2202/36

  Diameter · CPC title

• A61K51/1275

  Fibers, textiles, slabbs, or sheets · CPC title

• A61K51/1248 Primary

  nanotubes · CPC title